Pharmacogenomics and Personalized Medicine: Translating Genetic Variation into Precision Therapeutics

Pharmacogenomics represents the convergence of pharmacology and genomics, investigating how an individual's genetic constitution modulates drug response. Although the conceptual origins of pharmacogenetics trace back to observations in the 1950s regarding inherited variations in drug metabolism, the field expanded dramatically following the completion of the Human Genome Project in 2003. The transition from pharmacogenetics—traditionally focused on single-gene effects—to pharmacogenomics, which encompasses genome-wide analyses, has enabled a more comprehensive understanding of the genetic architecture underlying drug disposition and action.^[1][2][3]

In modern healthcare, pharmacogenomics occupies a central position within precision medicine, a paradigm that seeks to tailor prevention and treatment strategies to individual patient characteristics. The traditional "one-size-fits-all" approach to pharmacotherapy often results in suboptimal outcomes; approximately 30–50% of prescribed medications fail to produce the intended therapeutic effect, while ADRs remain a leading cause of morbidity and hospitalization worldwide. By elucidating the genetic determinants of drug metabolism, transport, and target sensitivity, pharmacogenomics facilitates predictive prescribing, thereby maximizing efficacy while minimizing toxicity.^[4][5][6][7]

The scope of this review encompasses the mechanistic principles of pharmacogenomics, the identification and validation of pharmacogenomic biomarkers, clinical applications across major therapeutic domains, enabling technologies, and the benefits and limitations of widespread implementation. Furthermore, this article examines current regulatory frameworks, global initiatives, and emerging trends that will shape the future trajectory of genotype-directed therapeutics.

2. Principles and Mechanisms of Pharmacogenomics

2.1 Genetic Variations Influencing Drug Response

Interindividual differences in drug response are multifactorial, arising from environmental, physiological, and genetic influences. Genetic variation accounts for an estimated 20–95% of variability in drug metabolism and disposition, depending on the specific therapeutic agent. The primary genetic determinants include single nucleotide polymorphisms (SNPs), copy number variations (CNVs), insertions/deletions, and structural rearrangements, each capable of altering protein function, expression, or stability.^[8][9]

2.2 Single Nucleotide Polymorphisms

SNPs constitute the most abundant form of genetic variation, occurring approximately once every 300 base pairs throughout the human genome. Within pharmacogenomics, coding-region SNPs may produce amino acid substitutions that alter enzyme catalytic activity, while non-coding variants can influence gene expression through modulation of transcription factor binding, splicing efficiency, or messenger RNA stability. The cytochrome P450 (CYP) enzyme superfamily exemplifies this phenomenon; polymorphisms in CYP2D6, CYP2C19, CYP2C9, and CYP3A4/5 generate distinct metabolizer phenotypes—ultrarapid, extensive, intermediate, and poor metabolizers—with profound implications for substrate drug exposure.^{[10][11][12][13]}

2.3 Copy Number Variations and Structural Variation

CNVs, involving duplications or deletions of genomic segments, contribute to dosage-sensitive phenotypes. The CYP2D6 gene exhibits particularly complex structural variation, with copy numbers ranging from zero to more than thirteen copies, directly correlating with enzyme activity and substrate clearance. Similarly, CNVs affecting drug transporters such as ABCB1 and SLCO1B1 modulate intracellular drug concentrations and tissue distribution.^[14][15]

2.4 Gene Expression and Epigenetics

Beyond germline sequence variation, epigenetic modifications—including DNA methylation, histone acetylation, and non-coding RNA regulation—dynamically alter gene expression without changing the underlying DNA sequence . Epigenetic silencing of drug-metabolizing enzymes in tumor tissues, for instance, can confer chemoresistance, while methylation patterns in TPMT promoter regions may influence thiopurine sensitivity . The interplay between genetic and epigenetic factors underscores the complexity of predicting drug response from genotype alone.

2.5 Pharmacokinetic and Pharmacodynamic Pathways

Pharmacogenomic influence extends across the entire pharmacological continuum. Pharmacokinetic pathways encompass absorption (e.g., ABCB1 in intestinal P-glycoprotein), distribution (e.g., SLCO1B1 in hepatic statin uptake), metabolism (e.g., CYP superfamily), and excretion (e.g., ABCC2 in renal and biliary efflux) . Pharmacodynamic pathways involve drug targets (e.g., VKORC1 in warfarin sensitivity), downstream signaling cascades, and disease-modifying genes . A comprehensive pharmacogenomic assessment must therefore integrate both kinetic and dynamic determinants to optimize therapeutic outcomes.

3. Pharmacogenomic Biomarkers

3.1 Definition and Significance

A pharmacogenomic biomarker is a defined characteristic—typically a DNA sequence variant—that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention . Validated biomarkers enable clinicians to stratify patients according to predicted drug response, thereby informing dose selection, contraindications, or therapeutic alternatives .

3.2 Identification and Validation

The biomarker development pipeline proceeds through analytical validation, clinical validation, and clinical utility assessment . Analytical validation confirms that a genotyping assay accurately and reproducibly detects the variant of interest. Clinical validation establishes a statistically significant association between the biomarker and a drug-related phenotype. Clinical utility, the most stringent criterion, requires evidence that biomarker-guided therapy improves meaningful clinical outcomes compared to standard care . The FDA classifies pharmacogenomic biomarkers in drug labeling according to these evidentiary tiers, distinguishing between mandatory testing requirements, recommended testing, and informational annotations .

3.3 Regulatory Perspectives

As of 2025, the FDA Table of Pharmacogenetic Associations encompasses over 400 biomarker-drug pairs spanning approximately 300 drugs, with one-third related to metabolism or transport, 41% to target pathways, and 26% to immunologic or safety mechanisms . The EMA has similarly integrated pharmacogenomic considerations into regulatory assessments, requiring risk management plans for agents with documented genetic predispositions to severe toxicity . The CPIC and DPWG have translated this regulatory evidence into standardized, peer-reviewed clinical guidelines that specify therapeutic recommendations based on genotype .

3.4 Clinical Relevance

The clinical relevance of a pharmacogenomic biomarker depends on the magnitude of the gene-drug interaction, the severity of the associated clinical outcome, and the availability of therapeutic alternatives . High-impact biomarkers—such as HLA-B alleles associated with severe cutaneous adverse reactions or TPMT variants predisposing to life-threatening myelosuppression—warrant preemptive genotyping due to the irreversible nature of the adverse outcomes .

4.Clinical Applications of Pharmacogenomics

4.1 Oncology

Oncology represents the therapeutic domain in which pharmacogenomics has achieved the deepest clinical penetration. Germline polymorphisms in TPMT and NUDT15 profoundly influence thiopurine toxicity; patients harboring two non-functional TPMT alleles (poor metabolizers) require dose reductions of up to 90% to avoid severe myelosuppression . Similarly, DPYD variants impair fluoropyrimidine catabolism, predisposing carriers to lethal toxicities following 5-fluorouracil or capecitabine administration; current CPIC and DPWG guidelines mandate preemptive testing with dose modification or alternative therapy for deficient metabolizers . The CYP2D6 genotype has been extensively investigated in tamoxifen metabolism, where reduced enzyme activity may compromise conversion to the active endoxifen metabolite, although routine clinical utility remains debated pending prospective outcome data . Recent regulatory updates from the FDA and National Comprehensive Cancer Network (NCCN) have strengthened recommendations for fluoropyrimidine toxicity screening .

4.2 Cardiology

Cardiovascular pharmacogenomics has matured considerably, particularly regarding anticoagulant and antiplatelet therapy. CYP2C9 and VKORC1 polymorphisms account for approximately 35–50% of interindividual warfarin dose variability, prompting the development of pharmacogenomic dosing algorithms that integrate genotype with clinical factors . In antiplatelet therapy, CYP2C19 loss-of-function alleles diminish clopidogrel bioactivation, increasing cardiovascular event risk in acute coronary syndrome patients; CPIC guidelines recommend alternative P2Y12 inhibitors (prasugrel or ticagrelor) for intermediate and poor metabolizers when clinically appropriate . Notably, 2025 updates regarding SLCO1B1 allele reclassification have refined statin safety protocols, recognizing this transporter variant as a critical determinant of simvastatin-induced myopathy risk .

4.3 Psychiatry

Psychiatric pharmacogenomics focuses predominantly on CYP-mediated metabolism of antidepressants and antipsychotics. CYP2D6 poor metabolizers exhibit elevated plasma concentrations of paroxetine, venlafaxine, and vortioxetine, increasing vulnerability to adverse effects; conversely, ultrarapid metabolizers may experience subtherapeutic exposure . CYP2C19 polymorphisms similarly affect citalopram, escitalopram, and sertraline metabolism, with the FDA recommending a 50% dose reduction or a maximum daily dose of 20 mg for CYP2C19 poor metabolizers prescribed citalopram due to QT prolongation risk . CPIC guidelines provide graded therapeutic recommendations for selective serotonin reuptake inhibitors and tricyclic antidepressants based on combined CYP2D6 and CYP2C19 genotypes .

4.4 Neurology

In neurology, HLA-B alleles have transformed the safety profile of antiepileptic drugs. HLA-B15:02 carriage is strongly associated with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in specific populations, leading to CPIC recommendations that exclude carbamazepine use in positive patients . HLA-B57:01 screening is mandatory prior to abacavir initiation in HIV therapy, virtually eliminating immunologically mediated hypersensitivity reactions . These examples illustrate how pharmacogenomics can prevent severe, idiosyncratic adverse reactions through preemptive genetic screening.

4.5 Infectious Diseases

Beyond abacavir hypersensitivity, pharmacogenomics informs antiretroviral and antiviral therapy through CYP and transporter polymorphisms that modulate drug exposure and drug-drug interaction potential in highly active antiretroviral therapy regimens . In tuberculosis management, NAT2 acetylator status influences isoniazid hepatotoxicity risk and dosing optimization .

4.6 Pain Management

Opioid analgesia is significantly influenced by CYP2D6 activity, which mediates the bioactivation of codeine to morphine and tramadol to O-desmethyltramadol. Poor metabolizers derive minimal analgesic benefit from codeine, while ultrarapid metabolizers—particularly pediatric and postoperative patients—are at heightened risk of life-threatening respiratory depression . Regulatory agencies in multiple jurisdictions have consequently restricted codeine use in children and breastfeeding mothers, with pharmacogenomic testing increasingly recommended for individualized opioid selection .

5. Technologies Used in Pharmacogenomic Research

5.1 Next-Generation Sequencing

Next-generation sequencing (NGS) technologies have revolutionized pharmacogenomic discovery by enabling high-throughput, cost-effective interrogation of genetic variation across coding and non-coding regions . Targeted NGS panels focusing on pharmacogenes offer a balanced approach, providing comprehensive allele coverage—including rare and novel variants—while maintaining manageable data volumes and interpretive workflows .

5.2 Whole Genome and Exome Sequencing

Whole genome sequencing (WGS) and whole exome sequencing (WES) facilitate unbiased discovery of pharmacogenomic associations without a priori gene selection. WGS captures regulatory and intronic variants potentially missed by exome-focused approaches, though data storage, computational demands, and variant interpretation complexities remain substantial barriers to routine clinical deployment .

5.3 Microarray Technology

Single nucleotide polymorphism arrays and pharmacogenomic-specific bead chips provide rapid, standardized genotyping for established star alleles and common variants. These platforms dominate current clinical testing due to their cost efficiency, reproducibility, and compatibility with automated laboratory workflows . However, they may fail to detect rare variants, structural rearrangements, or novel alleles, necessitating supplementary sequencing for comprehensive phenotyping.

5.4 Bioinformatics and Artificial Intelligence

The interpretation of pharmacogenomic data relies heavily on bioinformatics pipelines incorporating variant calling, annotation, and functional prediction algorithms . Artificial intelligence (AI) and machine learning models are increasingly employed to predict drug-gene interactions, polygenic risk scores for ADRs, and optimal dosing regimens by integrating genomic, clinical, and demographic variables . AI-driven pharmacogenomics holds particular promise for identifying complex, multi-gene interactions that escape traditional univariate analyses.

5.5 Precision Medicine Platforms

Integrated clinical decision support systems (CDSS) embedded within electronic health records represent the technological infrastructure necessary for clinical pharmacogenomic implementation . These platforms automatically alert prescribers to gene-drug interactions, recommend genotype-guided dosing, and document therapeutic decisions, thereby reducing cognitive burden and preventing human error .

6. Benefits of Pharmacogenomics

6.1 Improved Efficacy

By aligning drug selection with metabolic capacity and target sensitivity, pharmacogenomics enhances the probability of therapeutic success. Genotype-guided antidepressant prescribing, for instance, has demonstrated superior remission rates compared to empiric selection in randomized trials . In oncology, TPMT and DPYD testing prevents treatment discontinuation due to toxicity, enabling patients to maintain potentially curative chemotherapy regimens .

6.2 Reduced Adverse Drug Reactions

Preemptive pharmacogenomic screening directly prevents severe, genetically predetermined ADRs. HLA-B57:01 testing before abacavir prescription has reduced hypersensitivity incidence from approximately 8% to near zero . Similarly, HLA-B15:02 screening in at-risk populations has dramatically decreased carbamazepine-induced severe cutaneous adverse reactions .

6.3 Cost-Effectiveness

Although pharmacogenomic testing incurs upfront costs, economic analyses suggest that preventing ADRs, hospitalizations, and therapeutic failures yields favorable cost-effectiveness ratios . Preemptive panel-based testing—where multiple pharmacogenes are assayed simultaneously and results are stored for lifelong clinical use—may offer particularly attractive economic profiles by amortizing testing costs across numerous future prescriptions .

6.4 Optimized Dosage Selection

Pharmacogenomic algorithms refine dosing precision, reducing the prolonged titration periods characteristic of empiric prescribing. Warfarin pharmacogenomic dosing models incorporating CYP2C9 and VKORC1 genotypes achieve therapeutic anticoagulation more rapidly than clinical algorithms alone .

6.5 Enhanced Patient Outcomes

Collectively, these benefits translate into measurable improvements in patient safety, quality of life, and treatment satisfaction. The transition from reactive to predictive prescribing aligns with contemporary patient-centered care paradigms, fostering shared decision-making and therapeutic trust .

7. Challenges and Limitations

7.1 Genetic Diversity Among Populations

A critical limitation of current pharmacogenomic knowledge is its skew toward populations of European ancestry. Allele frequencies for clinically actionable variants differ substantially across ethnic groups; CYP2D6 ultrarapid metabolizer prevalence reaches 30% in North African and Middle Eastern populations but remains below 5% in East Asian cohorts . HLA-B15:02 is rare in European populations but present in 5–10% of individuals from certain Asian regions, necessitating population-specific screening strategies . The underrepresentation of African, Indigenous, and global South populations in genomic research perpetuates health disparities and limits the generalizability of pharmacogenomic guidelines .

7.2 Limited Clinical Implementation

Despite extensive evidence and available guidelines, pharmacogenomic testing remains inconsistently integrated into clinical practice. A 2024 systematic review highlighted that while healthcare professionals generally express positive attitudes toward pharmacogenomics, actual adoption is hindered by insufficient education, unclear reimbursement pathways, and lack of institutional infrastructure . The speed of adoption varies considerably according to national healthcare resources and regulatory maturity .

7.3 Ethical and Legal Concerns

Pharmacogenomic testing raises complex ethical questions regarding informed consent, incidental findings, and genetic discrimination. The detection of pharmacogenomic variants may reveal carrier status for heritable conditions unrelated to drug response, creating dilemmas about disclosure obligations and patient autonomy . Legislation such as the Genetic Information Nondiscrimination Act in the United States offers partial protections, but comprehensive legal frameworks remain absent in many jurisdictions .

7.4 Data Privacy Issues

The storage and transmission of genetic data within electronic health records introduce significant cybersecurity and privacy risks. Unlike passwords, genetic information is immutable, rendering breaches potentially lifelong threats to patient confidentiality . Robust encryption, access controls, and governance frameworks are essential to maintain public trust in pharmacogenomic programs.

7.5 Economic Barriers

Reimbursement for pharmacogenomic testing remains fragmented. In many healthcare systems, testing is not universally covered by insurance, creating access disparities that disproportionately affect marginalized populations . Demonstrating cost-effectiveness through prospective implementation studies is critical to securing sustainable funding from ministries of health and private insurers.

7.6 Healthcare Professional Training Gaps

Effective pharmacogenomic implementation requires a genetically literate workforce. Surveys consistently identify knowledge deficits among physicians, pharmacists, and nurses regarding gene-drug interactions, interpretation of test results, and application of dosing guidelines . Integration of pharmacogenomics into medical, pharmacy, and nursing curricula, alongside continuing professional development programs, represents an urgent priority .

8. Pharmacogenomics in Personalized Medicine

8.1 Integration into Clinical Practice

The realization of personalized medicine depends on embedding pharmacogenomic data into routine clinical workflows. Preemptive genotyping—where patients are screened for actionable pharmacogenes before prescribing—contrasts with reactive testing triggered by adverse events or therapeutic failure . Preemptive models are increasingly favored because they provide immediate decision support at the point of prescribing, avoiding delays in critical therapeutic contexts .

8.2 Precision Therapeutics

Precision therapeutics extends beyond pharmacogenomics to incorporate somatic tumor profiling, pharmacokinetic monitoring, and patient-specific comorbidities. In oncology, the combination of germline pharmacogenomic variants and somatic tumor mutations enables multidimensional treatment optimization . This integrative approach exemplifies the broader vision of personalized medicine, wherein therapeutic regimens are uniquely configured for individual patients rather than disease categories.

8.3 Individualized Treatment Planning

Pharmacogenomic data facilitate the construction of personalized medication plans that account for predicted efficacy, toxicity risk, and drug-drug interaction potential. Polypharmacy in elderly populations, for example, presents complex interaction matrices that pharmacogenomic profiles can help disentangle, reducing the risk of cascading ADRs in multimorbid patients .

8.4 Role in Future Healthcare Systems

As healthcare systems transition toward value-based care models, pharmacogenomics offers a mechanism to improve outcomes while controlling costs. Population-level pharmacogenomic screening programs, such as those piloted in the Netherlands and the United States, demonstrate the feasibility of large-scale implementation and provide templates for national precision medicine initiatives .

9. Current Regulatory Guidelines and Global Initiatives

9.1 FDA Recommendations

The FDA has been instrumental in advancing pharmacogenomic regulation through guidance documents on voluntary genomic data submission, pharmacogenomic tests for heritable markers, and the integration of pharmacogenomic information into drug labeling . The agency maintains a publicly accessible Table of Pharmacogenetic Associations that categorizes biomarkers as actionable, informative, or descriptive, thereby guiding prescribers and test developers . In 2025, the FDA and NCCN issued strengthened communications regarding fluoropyrimidine toxicity and DPYD testing, reflecting evolving regulatory commitment to pharmacogenomic safety .

9.2 EMA Guidelines

The EMA has adopted a complementary approach, embedding pharmacogenomic considerations within the evaluation of marketing authorization applications and risk management plans . The agency emphasizes post-marketing surveillance of genetically stratified adverse events and encourages the inclusion of pharmacogenomic substudies in clinical trials .

9.3 CPIC Guidelines

The Clinical Pharmacogenetics Implementation Consortium publishes peer-reviewed, evidence-based guidelines that translate genetic test results into specific prescribing recommendations . CPIC guidelines employ a standardized grading system for evidence quality and recommendation strength, covering gene-drug pairs including CYP2D6-codeine, CYP2C19-clopidogrel, TPMT-thiopurines, and DPYD-fluoropyrimidines . These guidelines are freely accessible and regularly updated, serving as the de facto international standard for clinical pharmacogenomic decision-making.

9.4 PharmGKB Database

The Pharmacogenomics Knowledge Base (PharmGKB) curates, annotates, and disseminates pharmacogenomic evidence from the primary literature, providing a critical resource for researchers and clinicians . PharmGKB Clinical Annotations assign levels of evidence to gene-drug associations and link to corresponding CPIC guidelines, FDA labels, and DPWG recommendations .

9.5 International Pharmacogenomic Programs

Globally, pharmacogenomic implementation efforts vary in scope and maturity. The Dutch Pharmacogenetics Working Group has integrated pharmacogenomic dosing recommendations into national medication surveillance systems . In the United States, the Implementing Genomics in Practice (IGNITE) network and the All of Us Research Program are advancing pharmacogenomic implementation science . Asian nations, including Japan, South Korea, and China, have launched population-specific pharmacogenomic research initiatives, though significant gaps remain in Indigenous and African populations . The absence of a unified global network of experts has been identified as a fundamental challenge impeding coordinated progress and equitable distribution of pharmacogenomic benefits .

10. Future Perspectives

10.1 AI-Driven Pharmacogenomics

The integration of machine learning and deep learning algorithms with pharmacogenomic datasets promises to unravel complex, polygenic influences on drug response that exceed human interpretive capacity . AI-driven models incorporating multi-omic, clinical, and environmental variables may ultimately enable fully individualized dosing predictions with quantified confidence intervals .

10.2 Multi-Omics Integration

Future precision medicine will transcend genomics to incorporate transcriptomics, proteomics, metabolomics, and epigenomic data. Multi-omics integration captures the dynamic, context-dependent nature of biological systems, offering a more nuanced portrait of drug response than static genotype alone . Pharmacometabolomics, for instance, can identify real-time biomarkers of therapeutic efficacy and toxicity, complementing preemptive genetic screening .

10.3 Digital Health Technologies

Wearable biosensors, mobile health applications, and remote monitoring platforms provide continuous phenotypic data that can refine pharmacogenomic predictions in real time . The convergence of digital health and pharmacogenomics supports closed-loop therapeutic systems where dosing is dynamically adjusted based on integrated genetic and physiological feedback.

10.4 Population Genomics

Large-scale biobanking and population genomic initiatives, including the UK Biobank and the All of Us program, are generating unprecedented datasets for pharmacogenomic discovery . These resources enable the identification of rare, population-specific variants with large effect sizes and facilitate the development of ancestry-aware predictive models .

10.5 Emerging Therapeutic Opportunities

Pharmacogenomics is expanding beyond small-molecule drugs to encompass biologics, cell therapies, and gene editing interventions. The pharmacogenomics of immunogenicity against monoclonal antibodies, for example, represents an emerging frontier with implications for autoimmune and oncologic therapeutics . Furthermore, CRISPR-based gene editing may eventually correct deleterious pharmacogenomic variants, transforming pharmacogenomics from a predictive to a curative discipline.

CONCLUSION

Pharmacogenomics has transitioned from theoretical promise to clinical reality, offering a robust scientific foundation for personalized medicine. The identification of actionable gene-drug interactions across oncology, cardiology, psychiatry, and infectious diseases demonstrates the tangible capacity of genetic information to improve therapeutic efficacy and prevent severe adverse reactions. Regulatory frameworks established by the FDA and EMA, alongside implementation guidelines from CPIC and DPWG, provide the structural scaffolding necessary for clinical adoption. Nevertheless, significant challenges persist, including population genetic diversity, economic barriers, educational deficits, and ethical complexities surrounding genetic data stewardship. The future of pharmacogenomics lies in the integration of artificial intelligence, multi-omics platforms, and digital health technologies within harmonized global implementation frameworks. As the field matures, the imperative to ensure equitable access across all populations must remain central to the precision medicine agenda. Ultimately, pharmacogenomics represents not merely an adjunct to modern pharmacotherapy but a fundamental reimagining of how medicines are selected, dosed, and monitored—anchoring the practice of medicine in the biological uniqueness of each patient.

REFERENCES

1. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364 (12):1144-1153. doi:10.1056/NEJMra1010600
2. Mancinelli L, Cronin M, Sadee W. Pharmacogenomics: the promise of personalized medicine. AAPS PharmSci. 2000;2 (1):E4. doi:10.1208/ps020104
3. Evans WE, McLeod HL. Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med. 2003;348 (6):538-549. doi:10.1056/NEJMra020526
4. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372 (9):793-795. doi:10.1056/NEJMp1500523
5. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329 (7456):15-19. doi:10.1136/bmj.329.7456.15
6. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116 (3):496-526. doi:10.1016/j.pharmthera.2007.09.004
7. Weinshilboum R, Wang L. Pharmacogenomics: precision medicine and drug response. Mayo Clin Proc. 2017;92 (11):1711-1722. doi:10.1016/j.mayocp.2017.09.016
8. Kalow W. Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics J. 2006;6 (3):162-165. doi:10.1038/sj.tpj.6500361
9. Lauschke VM, Milani L, Ingelman-Sundberg M. Pharmacogenomic biomarkers for improved drug therapy—recent progress and future developments. AAPS J. 2018;20 (1):4. doi:10.1208/s12248-017-0161-x
10. Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001;409 (6822):928-933. doi:10.1038/35057149
11. Wang L, Weinshilboum R. Pharmacogenomics: candidate gene identification, functional validation and mechanisms. Hum Mol Genet. 2008;17 (R2):R174-R181. doi:10.1093/hmg/ddn271
12. Zhou SF, Di YM, Chan E, et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab. 2008;9 (8):738-784. doi:10.2174/138920008786049302
13. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138 (1):103-141. doi:10.1016/j.pharmthera.2012.12.007
14. Gaedigk A, Ingelman-Sundberg M, Miller NA, et al. The Pharmacogene Variation (PharmVar) Consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin Pharmacol Ther. 2018;103 (3):399-401. doi:10.1002/cpt.910
15. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther. 2010;87 (1):130-133. doi:10.1038/clpt.2009.196
16. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31 (1):27-36. doi:10.1093/carcin/bgp220
17. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase model. Pharmacogenomics. 2000;1 (1):33-41. doi:10.1517/phgs.1.1.33.228325
18. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9 (3):215-236. doi:10.1038/nrd3028
19. Lee MT, Klein TE. Pharmacogenomics of warfarin: challenges and opportunities. J Hum Genet. 2013;58 (6):334-338. doi:10.1038/jhg.2013.40
20. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69 (3):89-95. doi:10.1067/mcp.2001.113989